Compare JetBlue Airways Corporation (JBLU) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs TransMedics Group Inc — how do they compare? JetBlue Airways Corporation trades at $3.84 (market cap $1.48B), while TransMedics Group Inc trades at $77.87 (market cap $2.74B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and TransMedics Group Inc is trading nearer its 52-week high, JetBlue Airways Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JetBlue Airways Corporation for 44 Days and TransMedics Group Inc for 24 Days on average.
| JBLU | TMDX | |
|---|---|---|
Market Cap | $1.48B | $2.74B |
Volume | 30,275,693 | 949,331 |
Sector | Industrials | Health |
52-Week High | $6.46 | $150.42 |
52-Week Low | $3.92 | $61.99 |
Typical Hold Time | 44 Days | 24 Days |
Enterprise Value | $8.84B | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.92, down 1.26% with a bearish technical outlook. The airline faces fundamental challenges with negative net income margins (-9.32%) and declining revenue trends, though valuation metrics like P/S (0.15) appear attractive. Recent developments include route expansion to Colombia and new first-class seating, but the company continues to struggle with profitability amid high fuel costs and competitive pressures.
Investment outlook remains cautious with significant execution risks. While analyst consensus suggests moderate upside to the $5.89 price target, persistent losses and high debt levels (debt-to-asset ratio over 50%) create headwinds. The stock offers speculative value for investors betting on operational turnaround, but requires careful risk management given the challenging industry environment.
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
